Key facts
- It has raised $190K; the latest was Later Stage VC in Dec 2025.
- Notable investors include Russian Direct Investment Fund, AstraZeneca, Skolkovo Foundation, Startup Village, Unicorn Capital Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Target Medicals Group
- ·The full record, as it builds
Funding rounds
No funding rounds for Target Medicals Group are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Target Medicals Group
Developer of therapeutic drugs designed to treat a range of medical conditions. The company's platform offers aldosterone synthase inhibitors and drug development programs targeting infectious diseases, enabling healthcare providers and researchers to treat hormone-related conditions and drug-resistant infections.
- Sector
- Healthcare
- HQ
- Warsaw, Poland
- Founded
- 2015
- Employees
- 7
- Website
- target-medicals.com/
- Ownership
- Privately Held (backing)
Target Medicals Group doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Target Medicals Group shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Target Medicals Group in its N-PORT filings yet. We sweep new filings monthly.